Pharmaceutical composition for treating mantle cell lymphoma

A kind of technology of mantle cell lymphoma and composition, applied in the field of pharmaceutical composition for treating mantle cell lymphoma

Inactive Publication Date: 2021-01-29
JIANGSU UNIV
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, there is no relevant research report on the combined use of HSP90 inhibitors and BTK inhibitors for anti-tumor

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for treating mantle cell lymphoma
  • Pharmaceutical composition for treating mantle cell lymphoma
  • Pharmaceutical composition for treating mantle cell lymphoma

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0021] Example 1. Effect of Ibrutinib on the proliferation of mantle cell lymphoma Jeko-1

[0022] 1. Ibrutinib drug treatment: 10 mM Ibrutinib was diluted into different concentrations in gradients with DMSO, and 3 replicate wells were set for each concentration.

[0023] 2. Collect and culture healthy Jeko-1 cells, centrifuge at 300 g for 5 min, resuspend the culture medium, use a cell counting plate for cell counting, use a 24-well plate, and resuspend 600 μL of the culture medium according to the cell growth characteristics, each well contains 5×10 4 cells.

[0024] 3. Add different concentrations of Ibrutinib to each well, and put it in 37 ℃, 5% CO 2 They were cultured in a constant temperature incubator for 72 h and divided into experimental group and blank control group.

[0025] 4. Use the MTT method for cell proliferation detection: add 60 μL of 5 mg / mL MTT solution to each well, incubate in the incubator for 1.5 h, observe blue-purple formazan crystals under the m...

Embodiment 2

[0028] Example 2. Effect of Ibrutinib on the proliferation of mantle cell lymphoma Granta-519

[0029] 1. Ibrutinib drug treatment: 10 mM Ibrutinib was diluted into different concentrations in gradients with DMSO, and 3 replicate wells were set for each concentration.

[0030] 2. Collect and cultivate healthy Granta-519 cells, centrifuge at 300 g for 5 min, resuspend the medium, and use a cell counting plate for cell counting. Use a 24-well plate. According to the characteristics of cell growth, resuspend 600 μL of the medium, and each well contains 10×10 4 cells.

[0031] 3. Add different concentrations of Ibrutinib to each well, and put it in 37 ℃, 5% CO 2 They were cultured in a constant temperature incubator for 72 h and divided into experimental group and blank control group.

[0032]4. Use the MTT method for cell proliferation detection: add 60 μL of 5 mg / mL MTT solution to each well, incubate in the incubator for 1.5 h, observe blue-purple formazan crystals under the...

Embodiment 3

[0035] Example 3. Effect of Ganetespib on the proliferation of mantle cell lymphoma Jeko-1

[0036] 1. Ganetespib drug treatment: Dilute 10 mM Ganetespib with DMSO to different concentrations according to the gradient, and set 3 replicate wells for each concentration.

[0037] 2. Collect and cultivate healthy Jeko-1 cells, centrifuge at 300 g for 5 min, resuspend the medium, and use a cell counting plate for cell counting. Use a 24-well plate. According to the cell growth characteristics, resuspend 600 μL of the medium, and each well contains 5×10 4 cells.

[0038] 3. Add different concentrations of Ganetespib to each well, and put in 37 ℃, 5% CO 2 They were cultured in a constant temperature incubator for 72 h and divided into experimental group and blank control group.

[0039] 4. Use the MTT method for cell proliferation detection: add 60 μL of 5 mg / mL MTT solution to each well, incubate in the incubator for 1.5 h, observe blue-purple formazan crystals under the microsco...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the field of biological medicine, and particularly relates to a pharmaceutical composition for treating mantle cell lymphoma. The invention provides a pharmaceutical composition for treating mantle cell lymphoma, and particularly provides a new drug choice for mantle cell lymphoma drug treatment by combining an HSP90 inhibitor and a Bruton's tyrosine kinase inhibitor. After biological activity analysis, it is found that the Ibrutinib and Gantespib combined drug has an obvious inhibiting effect on mantle cell lymphoma Jeko1 and Granta519, the effect is remarkably superior to that of single drug, and the additive or synergistic effect is achieved. Compared with the traditional Ibrutinib single-drug therapy, the composition has the advantages that the action concentration of Ibrutinib can be reduced, the proliferation of mantle cell lymphoma can be obviously inhibited, and recurrence and acquired drug resistance events caused by single-drug Ibrutinib therapy are avoided. Meanwhile, a new theoretical support is provided for design, research and development of drugs, and great value is achieved in the aspects of research and treatment of mantle cell lymphoma.

Description

technical field [0001] The invention belongs to the field of biomedicine, in particular to a pharmaceutical composition for treating mantle cell lymphoma. Background technique [0002] Mantle cell lymphoma (MCL) is a highly malignant B-cell non-Hodgkin lymphoma. The clinical symptoms are usually highly aggressive and the prognosis is poor. For the initial treatment of MCL, the combination chemotherapy regimen of cytarabine or R-CHOP (rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone) is often used, and the initial response is often good . However, due to off-target effects and the interaction between molecular pathways, the recurrence rate is high and the cure rate is poor. At present, there is no effective treatment plan for the treatment of MCL, and it is urgent to explore its pathogenesis and find an effective treatment plan. [0003] The B cell receptor (BCR) signaling pathway plays an important role in the growth and proliferation of various B ce...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/519A61K31/4196A61P35/00
CPCA61K31/4196A61K31/519A61P35/00A61K2300/00
Inventor 王志新刘晗青屠志刚
Owner JIANGSU UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap